# US 2023/0406895 A1 · Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406895 A1
- Document ID: US20230406895A1
- Status: Published application
- Kind: A1
- Application number: 18/036,560
- Filed: 2021-11-12
- Published: 2023-12-21
- Earliest claimed: 2020-11-13
- Assignees: ModernaTX, Inc.
- Applicants: ModernaTX, Inc.
- Inventors: Jean C. Sung; David Reid; Alicia Anne Bicknell; Ana Cadete Pires; Jeffrey Hrkach
- Web page: https://patentgrep.com/patent/US20230406895A1

## CPC

- C07K 14/4712: {Cystic fibrosis}
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/6909: {Micelles formed by phospholipids}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 11/00: Drugs for disorders of the respiratory system
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure relates to delivery vehicles comprising payload molecules, e.g., mRNA or gene editing therapeutics for the treatment of cystic fibrosis (CF). Nucleic acid therapeutics (e.g., mRNAs) for use in the invention, when administered in vivo, encode cystic fibrosis transmembrane conductance regulator (CFTR). Nucleic acid therapeutics (e.g., mRNAs) of the disclosure increase and/or restore deficient levels of CFTR expression and/or activity in subjects. Nucleic acid therapeutics (e.g., mRNAs) of the disclosure further decrease abnormal accumulation of ammonia associated with deficient CFTR activity in subjects.

## Claims

### Claim 1

A messenger RNA (mRNA) comprising an open reading frame (ORF) encoding the cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide of SEQ ID NO:1, wherein the ORF is at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of SEQ ID NO:142.

### Claim 2 (depends on 1)

The mRNA of claim 1, wherein the mRNA comprises a 5′ untranslated region (UTR) comprising the nucleotide sequence of SEQ ID NO:25.

### Claim 3 (depends on 1)

The mRNA of claim 1, wherein the mRNA comprises a 5′ UTR comprising the nucleotide sequence of SEQ ID NO:24.

### Claim 4

A messenger RNA (mRNA) comprising a 5′ untranslated region (UTR) comprising the nucleotide sequence of SEQ ID NO:28 and an open reading frame (ORF) encoding the cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide of SEQ ID NO:1.

### Claim 5 (depends on 4)

The mRNA of claim 4, wherein the 5′ UTR comprises the nucleotide sequence of SEQ ID NO:25.

### Claim 6 (depends on 4)

The mRNA of claim 4, wherein the 5′ UTR comprises the nucleotide sequence of SEQ ID NO:24.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The mRNA of any one of claims 1 to 6, wherein the mRNA comprises a 3′ UTR comprising the nucleotide sequence of SEQ ID NO:45.

### Claim 8

A messenger RNA (mRNA) comprising a 3′ untranslated region (UTR) comprising the nucleotide sequence of SEQ ID NO:45 and an open reading frame (ORF) encoding the cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide of SEQ ID NO:1.

### Claim 9 (depends on 8)

The mRNA of claim 8, wherein the mRNA comprises a 5′ UTR comprising the nucleotide sequence of SEQ ID NO:28.

### Claim 10 (depends on 8)

The mRNA of claim 8, wherein the mRNA comprises a 5′ UTR comprising the nucleotide sequence of SEQ ID NO:24 or 25.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The mRNA of any one of claims 1 to 10, wherein the mRNA comprises a 5′ terminal cap comprising m7G-ppp-Gm-AG.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The mRNA of any one of claims 1 to 11, wherein the mRNA comprises a poly-A region comprising A100-UCUAG-A20-inverted deoxy-thymidine (SEQ ID NO:211).

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The mRNA of any one of claims 1 to 12, comprising the nucleotide sequence of SEQ ID NO:153.

### Claim 14

A messenger RNA (mRNA) comprising:
(i) a 5′ terminal cap comprising m7G-ppp-Gm-AG;
(ii) a 5′ untranslated region (UTR) comprising the nucleotide sequence of SEQ ID NO:25;
(iii) an open reading frame (ORF) encoding the cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide of SEQ ID NO:1, wherein the ORF comprises the nucleotide sequence of SEQ ID NO:142;
(iv) a 3′ UTR comprising the nucleic acid sequence of 45; and
(v) a poly-A region comprising A100-UCUAG-A20-inverted deoxy-thymidine (SEQ ID NO:211).

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The mRNA of any one of claims 1 to 14, wherein the mRNA comprises at least one chemically modified nucleobase, sugar, backbone, or any combination thereof.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The mRNA of any one of claims 1 to 14, wherein all of the uracils of the mRNA are N1-methylpseudouracils.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A pharmaceutical composition comprising the mRNA of any one of claims 1 to 16.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A lipid nanoparticle comprising the mRNA of any one of claims 1 to 16.

### Claim 19 (depends on 18)

The lipid nanoparticle of claim 18, wherein the lipid nanoparticle comprises:
a lipid nanoparticle core comprising:
(i) an ionizable lipid,
(ii) a phospholipid,
(iii) a structural lipid, and
(iv) a PEG-lipid, and
wherein the mRNA is encapsulated within the core, and
wherein the lipid nanoparticle core has been contacted with a cationic agent.

### Claim 20 (depends on 19)

The lipid nanoparticle of claim 19, wherein the cationic agent is GL-67:
or a salt thereof.

### Claim 21 (depends on 18)

The lipid nanoparticle of claim 18, wherein the lipid nanoparticle comprises:
(i) an ionizable lipid,
(ii) a phospholipid;
(iii) a structural lipid;
(iv) a PEG-lipid; and
(v) a cationic agent.

### Claim 22 (depends on 21)

The lipid nanoparticle of claim 21, wherein the cationic agent is a sterol amine.

### Claim 23 (depends on 21)

The lipid nanoparticle of claim 21, wherein the cationic agent is GL-67:
or a salt thereof.

### Claim 24

A lipid nanoparticle comprising:
(i)
or a salt thereof;
(ii)
or a salt thereof; and
(iii) a messenger RNA (mRNA) encoding a cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide.

### Claim 25 (depends on 24)

The lipid nanoparticle of claim 24, wherein the CFTR polypeptide comprises the amino acid sequence set forth in SEQ ID NO:1.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A process of preparing a nanoparticle comprising contacting a lipid nanoparticle core with a cationic agent, wherein the lipid nanoparticle comprises:
(a) a lipid nanoparticle core comprising:
(i) an ionizable lipid,
(ii) a phospholipid,
(iii) a structural lipid, and
(iv) a PEG-lipid, and
(b) the mRNA of any one of claims 1 to 16.

### Claim 27 (depends on 26)

The process of claim 26, wherein the contacting of the lipid nanoparticle core with a cationic agent comprises dissolving the cationic agent in a non-ionic excipient.

### Claim 28 (depends on 27)

The process of claim 27, wherein the non-ionic excipient is macrogol 15 hydroxystearate (HS 15).

### Claim 29 (depends on 25, 26, 27, 28)

The process of any one of claims 25 to 28, wherein the cationic agent is a sterol amine.

### Claim 30 (depends on 29)

The process of claim 29, wherein the sterol amine is GL-67:
or a salt thereof.

### Claim 31 (depends on 26, 27, 28, 29, 30)

A nanoparticle prepared by the process of any one of claims 26-30.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 31)

A method of treating or preventing cystic fibrosis in a human subject in need thereof, comprising administering to the subject the mRNA of any one of claims 1 to 16, the pharmaceutical composition of claim 17, the lipid nanoparticle of any one of claims 18 to 25, or the nanoparticle of claim 31.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 31)

A method of preventing cystic fibrosis in a human subject having cystic fibrosis-causing mutations in both copies of the CFTR gene, comprising administering to the subject the mRNA of any one of claims 1 to 16, the pharmaceutical composition of claim 17, the lipid nanoparticle of any one of claims 18 to 25, or the nanoparticle of claim 31.

### Claim 34 (depends on 33)

The method of claim 33, wherein the cystic fibrosis-causing mutations are selected from the group consisting of G542X, W1282X, R553X, F508del, N1303K, I507del, G551D, S549N, D1152H, R347P, and R117H.

### Claim 35 (depends on 32, 33, 34)

The method of any one of claims 32 to 34, wherein the administering is to the respiratory tract or lung of the subject.
